BIO-TECHNE Corp Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest
BIO-TECHNE Corp (TECH) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest of $0 for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest · last filed 2025-08-22
- BIO-TECHNE Corp other comprehensive income (loss), net of tax, portion attributable to noncontrolling interest for the quarter ending 2024-03-31 was $0.00.
- BIO-TECHNE Corp other comprehensive income (loss), net of tax, portion attributable to noncontrolling interest for the quarter ending 2023-06-30 was $0.00.
- BIO-TECHNE Corp other comprehensive income (loss), net of tax, portion attributable to noncontrolling interest for the quarter ending 2023-03-31 was $0.00.
- BIO-TECHNE Corp other comprehensive income (loss), net of tax, portion attributable to noncontrolling interest for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- BIO-TECHNE Corp other comprehensive income (loss), net of tax, portion attributable to noncontrolling interest for fiscal 2023 was -$33.00K.
- BIO-TECHNE Corp other comprehensive income (loss), net of tax, portion attributable to noncontrolling interest for fiscal 2022 was -$70.00K, a 167.96% decline from fiscal 2021.
- BIO-TECHNE Corp other comprehensive income (loss), net of tax, portion attributable to noncontrolling interest for fiscal 2021 was $103.00K.
- BIO-TECHNE Corp other comprehensive income (loss), net of tax, portion attributable to noncontrolling interest for fiscal 2020 was $0.00.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2024-03-31 | $0.00 10-Q · filed 2024-05-06 | $0.00 10-Q · filed 2024-05-06 | ||
| 2023-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-08-22 | $0.00 derived: sum of 2 quarters · filed 2025-08-22 | $0.00 derived: sum of 3 quarters · filed 2025-08-22 | -$33.00K 10-K · filed 2025-08-22 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-06 | $0.00 derived: sum of 2 quarters · filed 2024-05-06 | -$33.00K 10-Q · filed 2024-05-06 | -$129.00K derived: sum of 4 quarters · filed 2024-08-22 |
| 2022-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-07 | -$33.00K 10-Q · filed 2024-02-07 | -$129.00K derived: sum of 3 quarters · filed 2024-08-22 | -$130.00K derived: sum of 4 quarters · filed 2024-08-22 |
| 2022-09-30 | -$33.00K 10-Q · filed 2023-11-07 | -$129.00K derived: sum of 2 quarters · filed 2024-08-22 | -$130.00K derived: sum of 3 quarters · filed 2024-08-22 | -$64.00K derived: sum of 4 quarters · filed 2024-08-22 |
| 2022-06-30 | -$96.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-08-22 | -$97.00K derived: sum of 2 quarters · filed 2024-08-22 | -$31.00K derived: sum of 3 quarters · filed 2024-08-22 | -$70.00K 10-K · filed 2024-08-22 |
| 2022-03-31 | -$1.00K 10-Q · filed 2023-05-08 | $65.00K derived: sum of 2 quarters · filed 2023-05-08 | $26.00K 10-Q · filed 2023-05-08 | $115.00K derived: sum of 4 quarters · filed 2023-08-23 |
| 2021-12-31 | $66.00K 10-Q · filed 2023-02-07 | $27.00K 10-Q · filed 2023-02-07 | $116.00K derived: sum of 3 quarters · filed 2023-08-23 | $47.00K derived: sum of 4 quarters · filed 2023-08-23 |
| 2021-09-30 | -$39.00K 10-Q · filed 2022-11-07 | $50.00K derived: sum of 2 quarters · filed 2023-08-23 | -$19.00K derived: sum of 3 quarters · filed 2023-08-23 | $64.00K derived: sum of 4 quarters · filed 2023-08-23 |
| 2021-06-30 | $89.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-08-23 | $20.00K derived: sum of 2 quarters · filed 2023-08-23 | $103.00K derived: sum of 3 quarters · filed 2023-08-23 | $103.00K 10-K · filed 2023-08-23 |
| 2021-03-31 | -$69.00K 10-Q · filed 2022-05-09 | $14.00K derived: sum of 2 quarters · filed 2022-05-09 | $14.00K 10-Q · filed 2022-05-09 | $14.00K derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $83.00K 10-Q · filed 2022-02-07 | $83.00K 10-Q · filed 2022-02-07 | $83.00K derived: sum of 3 quarters · filed 2022-02-07 | $83.00K derived: sum of 4 quarters · filed 2022-02-07 |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-08 | $0.00 derived: sum of 2 quarters · filed 2021-11-08 | $0.00 derived: sum of 3 quarters · filed 2021-11-08 | $0.00 derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-08-25 | $0.00 derived: sum of 2 quarters · filed 2021-08-25 | $0.00 derived: sum of 3 quarters · filed 2021-08-25 | $0.00 10-K · filed 2021-08-25 |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-07 | $0.00 derived: sum of 2 quarters · filed 2021-05-07 | $0.00 10-Q · filed 2021-05-07 | |
| 2019-12-31 | $0.00 10-Q · filed 2021-02-08 | $0.00 10-Q · filed 2021-02-08 | ||
| 2019-06-30 | $0.00 10-K · filed 2021-08-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |